Literature DB >> 16384758

Treatment of recalcitrant atopic dermatitis with omalizumab.

Joshua E Lane1, Jason M Cheyney, Tanda N Lane, David E Kent, David J Cohen.   

Abstract

Atopic dermatitis is a common diagnosis that presents a therapeutic challenge. Although multiple therapeutic modalities exist, there is no single monotherapy that has proven exceptional in ameliorating the symptoms of this disease. Current topical and systemic therapeutic options offer benefit but carry varying degrees of adverse effects that often limit their application. We present 3 patients with severe, recalcitrant atopic dermatitis successfully treated with omalizumab.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16384758     DOI: 10.1016/j.jaad.2005.09.030

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  38 in total

Review 1.  Therapeutic perspectives in atopic dermatitis.

Authors:  Laurent Misery
Journal:  Clin Rev Allergy Immunol       Date:  2011-12       Impact factor: 8.667

2.  The effects of PG102, a water-soluble extract from Actinidia arguta, on serum total IgE levels: a double-blind, randomized, placebo-controlled exploratory clinical study.

Authors:  Sae-Hoon Kim; Sunyoung Kim; So-Hee Lee; Heung-Woo Park; Yoon-Seok Chang; Kyung-Up Min; Sang-Heon Cho
Journal:  Eur J Nutr       Date:  2010-12-25       Impact factor: 5.614

Review 3.  Systemic treatment of adult atopic dermatitis.

Authors:  Hannah Cookson; Catherine Smith
Journal:  Clin Med (Lond)       Date:  2012-04       Impact factor: 2.659

4.  Omalizumab for patients with severe and therapy-refractory atopic eczema?

Authors:  Christian Andres; Benedetta Belloni; Martin Mempel; Johannes Ring
Journal:  Curr Allergy Asthma Rep       Date:  2008-05       Impact factor: 4.806

Review 5.  Off-Label Uses of Omalizumab.

Authors:  David El-Qutob
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

Review 6.  Emerging therapeutic options for atopic dermatitis: beyond TIMs.

Authors:  Edward R Conner; Lisa A Beck
Journal:  Curr Allergy Asthma Rep       Date:  2006-07       Impact factor: 4.806

7.  Atopic dermatitis.

Authors:  Thomas Bieber
Journal:  Ann Dermatol       Date:  2010-05-17       Impact factor: 1.444

8.  [Status quo and prospects for systemic therapy of atopic dermatitis. Biologics ante portas].

Authors:  T Biedermann; T Werfel
Journal:  Hautarzt       Date:  2015-02       Impact factor: 0.751

Review 9.  Systemic therapy of atopic dermatitis in children.

Authors:  Giampaolo Ricci; Arianna Dondi; Annalisa Patrizi; Massimo Masi
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 10.  Immunoglobulin E in irritable bowel syndrome: another target for treatment? A case report and literature review.

Authors:  James S Pearson; Robert M Niven; Jie Meng; Sima Atarodi; Peter J Whorwell
Journal:  Therap Adv Gastroenterol       Date:  2015-09       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.